The Food and Drug Administration is already limiting one of the most controversial drug approvals in its 115-year history.
The medication is Biogen Inc.’s Alzheimer’s treatment Aduhelm, which won clearance recently despite mixed evidence and expert objections. The agency initially approved the drug for most Alzheimer’s patients, even though it was only studied in those with mild disease.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.